Sichuan Kelun-biotech Biopharmaceutical Co., Ltd.

This study is testing an investigational drug called SKB264 for people with advanced triple-negative breast cancer that has spread or returned and has not responded to at least two prior standard treatments. The goal is to see if SKB264 works better than other chemotherapy option…

This early-stage study is testing a new drug called A166 in people with advanced HER2-positive solid tumors that have spread or cannot be removed by surgery. The main goals are to find a safe dose and see if the drug shows early signs of helping shrink tumors. The study will enro…

This study is testing two experimental drug combinations for people with advanced HER2-negative breast cancer that cannot be removed by surgery. Researchers want to see if adding a second drug (KL-A167) to the main treatment (SKB264) works better than using SKB264 alone. The tria…

This study is comparing a new drug called SKB264 against standard chemotherapy for people with advanced non-small cell lung cancer. It's for patients whose cancer has a specific genetic change (EGFR mutation) and has continued to grow despite initial targeted therapy. The trial a…

This study is testing if a new drug called SKB264 works better when combined with the standard immunotherapy drug pembrolizumab for people with advanced non-small cell lung cancer. It's for patients who haven't had any prior treatment for their advanced cancer and whose tumors ha…

This study is testing an investigational capsule called KL590586 for adults with advanced solid tumors that have specific changes in a gene called RET. The main goals are to find a safe dose and see if the treatment can shrink tumors. It is for people whose cancer has progressed …